| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.
|
Nat Med
|
2004
|
2.93
|
|
2
|
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.
|
J Immunol
|
2004
|
2.33
|
|
3
|
Pathogen recognition and development of particulate vaccines: does size matter?
|
Methods
|
2006
|
2.09
|
|
4
|
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.
|
Vaccine
|
2002
|
1.97
|
|
5
|
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling.
|
Nat Commun
|
2013
|
1.71
|
|
6
|
Natural regulatory T cells and persistent viral infection.
|
J Virol
|
2007
|
1.62
|
|
7
|
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria.
|
PLoS Pathog
|
2009
|
1.46
|
|
8
|
Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films.
|
Malar J
|
2008
|
1.35
|
|
9
|
Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
|
Mol Pharm
|
2007
|
1.34
|
|
10
|
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses.
|
J Infect Dis
|
2008
|
1.28
|
|
11
|
Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans.
|
PLoS One
|
2008
|
1.25
|
|
12
|
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection.
|
Am J Trop Med Hyg
|
2003
|
1.22
|
|
13
|
A regulatory role for CD37 in T cell proliferation.
|
J Immunol
|
2004
|
1.20
|
|
14
|
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.
|
Vaccine
|
2006
|
1.16
|
|
15
|
Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta.
|
PLoS Pathog
|
2009
|
1.14
|
|
16
|
Heroes or villains? T regulatory cells in malaria infection.
|
Trends Parasitol
|
2009
|
1.12
|
|
17
|
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity.
|
Methods
|
2006
|
1.11
|
|
18
|
Vaccines that facilitate antigen entry into dendritic cells.
|
Immunol Cell Biol
|
2004
|
1.09
|
|
19
|
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.
|
PLoS Pathog
|
2009
|
1.08
|
|
20
|
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.
|
Proc Natl Acad Sci U S A
|
2003
|
1.07
|
|
21
|
Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection.
|
Immunol Cell Biol
|
2007
|
1.06
|
|
22
|
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
|
Breast Cancer Res
|
2006
|
1.03
|
|
23
|
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect.
|
Infect Immun
|
2004
|
1.02
|
|
24
|
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.
|
Infect Immun
|
2002
|
1.02
|
|
25
|
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation.
|
Am J Trop Med Hyg
|
2006
|
1.00
|
|
26
|
Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
|
Vaccine
|
2004
|
1.00
|
|
27
|
Hot, sweet and sticky: the glycobiology of Plasmodium falciparum.
|
Trends Parasitol
|
2008
|
0.99
|
|
28
|
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design.
|
J Mol Biol
|
2002
|
0.96
|
|
29
|
The activin A antagonist follistatin inhibits asthmatic airway remodelling.
|
Thorax
|
2012
|
0.94
|
|
30
|
Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors.
|
J Mol Biol
|
2002
|
0.94
|
|
31
|
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria.
|
Infect Immun
|
2013
|
0.92
|
|
32
|
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
|
Infect Immun
|
2009
|
0.91
|
|
33
|
The challenge of assessing infant vaccine responses in resource-poor settings.
|
Expert Rev Vaccines
|
2010
|
0.90
|
|
34
|
Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers.
|
Methods
|
2013
|
0.89
|
|
35
|
Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming.
|
Eur J Immunol
|
2006
|
0.88
|
|
36
|
Systemic immune responses in sheep, induced by a novel nano-bead adjuvant.
|
Vaccine
|
2005
|
0.88
|
|
37
|
Selectively impaired CD8+ but not CD4+ T cell cycle arrest during priming as a consequence of dendritic cell interaction with plasmodium-infected red cells.
|
J Immunol
|
2005
|
0.86
|
|
38
|
The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells.
|
Methods
|
2013
|
0.86
|
|
39
|
A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity.
|
J Immunol
|
2010
|
0.86
|
|
40
|
Promising particle-based vaccines in cancer therapy.
|
Expert Rev Vaccines
|
2008
|
0.85
|
|
41
|
The good, the bad and the ugly: how altered peptide ligands modulate immunity.
|
Expert Opin Biol Ther
|
2008
|
0.85
|
|
42
|
Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1).
|
FEMS Microbiol Lett
|
2003
|
0.84
|
|
43
|
Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles.
|
Wiley Interdiscip Rev Nanomed Nanobiotechnol
|
2010
|
0.84
|
|
44
|
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
|
Clin Immunol
|
2013
|
0.84
|
|
45
|
Interleukin-13 regulates secretion of the tumor growth factor-{beta} superfamily cytokine activin A in allergic airway inflammation.
|
Am J Respir Cell Mol Biol
|
2009
|
0.83
|
|
46
|
Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints.
|
J Immunol
|
2013
|
0.83
|
|
47
|
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
|
Clin Cancer Res
|
2013
|
0.83
|
|
48
|
TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors.
|
Front Immunol
|
2013
|
0.82
|
|
49
|
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.
|
PLoS One
|
2012
|
0.82
|
|
50
|
Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation.
|
J Immunol
|
2011
|
0.81
|
|
51
|
CD38 identifies a hypo-proliferative IL-13-secreting CD4+ T-cell subset that does not fit into existing naive and memory phenotype paradigms.
|
Eur J Immunol
|
2011
|
0.81
|
|
52
|
The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
|
Malar J
|
2011
|
0.81
|
|
53
|
On the efficacy of malaria DNA vaccination with magnetic gene vectors.
|
J Control Release
|
2013
|
0.80
|
|
54
|
The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.
|
Diabetologia
|
2013
|
0.79
|
|
55
|
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
|
Am J Hematol
|
2014
|
0.78
|
|
56
|
Mannan-mediated gene delivery for cancer immunotherapy.
|
Immunology
|
2007
|
0.78
|
|
57
|
Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.
|
Cancers (Basel)
|
2012
|
0.77
|
|
58
|
Predicting memory: a prospective readout for malaria vaccines?
|
Trends Parasitol
|
2007
|
0.77
|
|
59
|
Phenotypic analysis of ovine antigen presenting cells loaded with nanoparticles migrating from the site of vaccination.
|
Methods
|
2013
|
0.77
|
|
60
|
Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads.
|
Vaccine
|
2008
|
0.77
|
|
61
|
Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep.
|
Vet Immunol Immunopathol
|
2013
|
0.76
|
|
62
|
Aspects of cancer immunotherapy.
|
Immunol Cell Biol
|
2003
|
0.76
|
|
63
|
N,N'-Carbonyldiimidazole-mediated functionalization of superparamagnetic nanoparticles as vaccine carrier.
|
Colloids Surf B Biointerfaces
|
2010
|
0.76
|
|
64
|
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
|
Br J Haematol
|
2015
|
0.75
|
|
65
|
Nanotechnology and vaccine development: methods to study and manipulate the interaction of nanoparticles with the immune system.
|
Methods
|
2013
|
0.75
|
|
66
|
Regulatory T-cells: immunomodulators in health and disease.
|
Curr Top Med Chem
|
2006
|
0.75
|
|
67
|
A new boost for malaria vaccines.
|
Trends Parasitol
|
2004
|
0.75
|
|
68
|
The effects of engineered nanoparticles on pulmonary immune homeostasis.
|
Drug Metab Rev
|
2013
|
0.75
|